Amanote Research
Register
Sign In
In Vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-04-2129
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
May 15, 2005
Authors
S. H. Lee
Publisher
American Association for Cancer Research (AACR)
Related search
CHIR-258, a Novel, Multitargeted Tyrosine Kinase Inhibitor for the Potential Treatment of T(4;14) Multiple Myeloma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study
Biomedical Journal
Medicine
SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models
Cancer Translational Medicine
Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
Insulin-Like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer
Clinical Cancer Research
Cancer Research
Oncology
ISO-66, a Novel Inhibitor of Macrophage Migration Inhibitory Factor, Shows Efficacy in Melanoma and Colon Cancer Models
International Journal of Oncology
Cancer Research
Oncology
The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis
Cancer Research
Cancer Research
Oncology
Correction: A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth in Vitro and in Vivo
Molecular Cancer Therapeutics
Cancer Research
Oncology
ZD1839 (‘Iressa’), a Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Model
British Journal of Cancer
Cancer Research
Oncology
